Literature DB >> 27335277

The genetics of nodal marginal zone lymphoma.

Valeria Spina1, Hossein Khiabanian2, Monica Messina3, Sara Monti1, Luciano Cascione4, Alessio Bruscaggin1, Elisa Spaccarotella1, Antony B Holmes5, Luca Arcaini6, Marco Lucioni7, Fabrizio Tabbò8, Sakellarios Zairis2, Fary Diop1, Michaela Cerri1, Sabina Chiaretti3, Roberto Marasca9, Maurilio Ponzoni10, Silvia Deaglio11, Antonio Ramponi12, Enrico Tiacci13, Laura Pasqualucci5, Marco Paulli7, Brunangelo Falini13, Giorgio Inghirami14, Francesco Bertoni4, Robin Foà3, Raul Rabadan2, Gianluca Gaidano1, Davide Rossi15.   

Abstract

Nodal marginal zone lymphoma (NMZL) is a rare, indolent B-cell tumor that is distinguished from splenic marginal zone lymphoma (SMZL) by the different pattern of dissemination. NMZL still lacks distinct markers and remains orphan of specific cancer gene lesions. By combining whole-exome sequencing, targeted sequencing of tumor-related genes, whole-transcriptome sequencing, and high-resolution single nucleotide polymorphism array analysis, we aimed at disclosing the pathways that are molecularly deregulated in NMZL and we compare the molecular profile of NMZL with that of SMZL. These analyses identified a distinctive pattern of nonsilent somatic lesions in NMZL. In 35 NMZL patients, 41 genes were found recurrently affected in ≥3 (9%) cases, including highly prevalent molecular lesions of MLL2 (also known as KMT2D; 34%), PTPRD (20%), NOTCH2 (20%), and KLF2 (17%). Mutations of PTPRD, a receptor-type protein tyrosine phosphatase regulating cell growth, were enriched in NMZL across mature B-cell tumors, functionally caused the loss of the phosphatase activity of PTPRD, and were associated with cell-cycle transcriptional program deregulation and increased proliferation index in NMZL. Although NMZL shared with SMZL a common mutation profile, NMZL harbored PTPRD lesions that were otherwise absent in SMZL. Collectively, these findings provide new insights into the genetics of NMZL, identify PTPRD lesions as a novel marker for this lymphoma across mature B-cell tumors, and support the distinction of NMZL as an independent clinicopathologic entity within the current lymphoma classification.
© 2016 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27335277      PMCID: PMC5016706          DOI: 10.1182/blood-2016-02-696757

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  68 in total

1.  Alteration of BIRC3 and multiple other NF-κB pathway genes in splenic marginal zone lymphoma.

Authors:  Davide Rossi; Silvia Deaglio; David Dominguez-Sola; Silvia Rasi; Tiziana Vaisitti; Claudio Agostinelli; Valeria Spina; Alessio Bruscaggin; Sara Monti; Michaela Cerri; Stefania Cresta; Marco Fangazio; Luca Arcaini; Marco Lucioni; Roberto Marasca; Catherine Thieblemont; Daniela Capello; Fabio Facchetti; Ivo Kwee; Stefano A Pileri; Robin Foà; Francesco Bertoni; Riccardo Dalla-Favera; Laura Pasqualucci; Gianluca Gaidano
Journal:  Blood       Date:  2011-08-31       Impact factor: 22.113

2.  Mutational and functional analysis of the tumor-suppressor PTPRD in human melanoma.

Authors:  Vijay Walia; Todd D Prickett; Jung-Sik Kim; Jared J Gartner; Jimmy C Lin; Ming Zhou; Steven A Rosenberg; Randolph C Elble; David A Solomon; Todd Waldman; Yardena Samuels
Journal:  Hum Mutat       Date:  2014-09-10       Impact factor: 4.878

3.  SF3B1 and other novel cancer genes in chronic lymphocytic leukemia.

Authors:  Lili Wang; Michael S Lawrence; Youzhong Wan; Petar Stojanov; Carrie Sougnez; Kristen Stevenson; Lillian Werner; Andrey Sivachenko; David S DeLuca; Li Zhang; Wandi Zhang; Alexander R Vartanov; Stacey M Fernandes; Natalie R Goldstein; Eric G Folco; Kristian Cibulskis; Bethany Tesar; Quinlan L Sievers; Erica Shefler; Stacey Gabriel; Nir Hacohen; Robin Reed; Matthew Meyerson; Todd R Golub; Eric S Lander; Donna Neuberg; Jennifer R Brown; Gad Getz; Catherine J Wu
Journal:  N Engl J Med       Date:  2011-12-12       Impact factor: 91.245

4.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

5.  KLF2 mutation is the most frequent somatic change in splenic marginal zone lymphoma and identifies a subset with distinct genotype.

Authors:  A Clipson; M Wang; L de Leval; M Ashton-Key; A Wotherspoon; G Vassiliou; N Bolli; C Grove; S Moody; L Escudero-Ibarz; G Gundem; K Brugger; X Xue; E Mi; A Bench; M Scott; H Liu; G Follows; E F Robles; J A Martinez-Climent; D Oscier; A J Watkins; M-Q Du
Journal:  Leukemia       Date:  2014-11-27       Impact factor: 11.528

6.  Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics.

Authors:  Roland Schmitz; Ryan M Young; Michele Ceribelli; Sameer Jhavar; Wenming Xiao; Meili Zhang; George Wright; Arthur L Shaffer; Daniel J Hodson; Eric Buras; Xuelu Liu; John Powell; Yandan Yang; Weihong Xu; Hong Zhao; Holger Kohlhammer; Andreas Rosenwald; Philip Kluin; Hans Konrad Müller-Hermelink; German Ott; Randy D Gascoyne; Joseph M Connors; Lisa M Rimsza; Elias Campo; Elaine S Jaffe; Jan Delabie; Erlend B Smeland; Martin D Ogwang; Steven J Reynolds; Richard I Fisher; Rita M Braziel; Raymond R Tubbs; James R Cook; Dennis D Weisenburger; Wing C Chan; Stefania Pittaluga; Wyndham Wilson; Thomas A Waldmann; Martin Rowe; Sam M Mbulaiteye; Alan B Rickinson; Louis M Staudt
Journal:  Nature       Date:  2012-08-12       Impact factor: 49.962

7.  Recurrent mutations of MYD88 and TBL1XR1 in primary central nervous system lymphomas.

Authors:  Alberto Gonzalez-Aguilar; Ahmed Idbaih; Blandine Boisselier; Naïma Habbita; Marta Rossetto; Alice Laurenge; Aurélie Bruno; Anne Jouvet; Marc Polivka; Clovis Adam; Dominique Figarella-Branger; Catherine Miquel; Anne Vital; Hervé Ghesquières; Rémy Gressin; Vincent Delwail; Luc Taillandier; Olivier Chinot; Pierre Soubeyran; Emmanuel Gyan; Sylvain Choquet; Caroline Houillier; Carole Soussain; Marie-Laure Tanguy; Yannick Marie; Karima Mokhtari; Khê Hoang-Xuan
Journal:  Clin Cancer Res       Date:  2012-07-26       Impact factor: 12.531

8.  Recurrent somatic mutations of PTPN1 in primary mediastinal B cell lymphoma and Hodgkin lymphoma.

Authors:  Jay Gunawardana; Fong Chun Chan; Adèle Telenius; Bruce Woolcock; Robert Kridel; King L Tan; Susana Ben-Neriah; Anja Mottok; Raymond S Lim; Merrill Boyle; Sanja Rogic; Lisa M Rimsza; Chrystelle Guiter; Karen Leroy; Philippe Gaulard; Corinne Haioun; Marco A Marra; Kerry J Savage; Joseph M Connors; Sohrab P Shah; Randy D Gascoyne; Christian Steidl
Journal:  Nat Genet       Date:  2014-02-16       Impact factor: 38.330

9.  The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development.

Authors:  Davide Rossi; Vladimir Trifonov; Marco Fangazio; Alessio Bruscaggin; Silvia Rasi; Valeria Spina; Sara Monti; Tiziana Vaisitti; Francesca Arruga; Rosella Famà; Carmela Ciardullo; Mariangela Greco; Stefania Cresta; Daniela Piranda; Antony Holmes; Giulia Fabbri; Monica Messina; Andrea Rinaldi; Jiguang Wang; Claudio Agostinelli; Pier Paolo Piccaluga; Marco Lucioni; Fabrizio Tabbò; Roberto Serra; Silvia Franceschetti; Clara Deambrogi; Giulia Daniele; Valter Gattei; Roberto Marasca; Fabio Facchetti; Luca Arcaini; Giorgio Inghirami; Francesco Bertoni; Stefano A Pileri; Silvia Deaglio; Robin Foà; Riccardo Dalla-Favera; Laura Pasqualucci; Raul Rabadan; Gianluca Gaidano
Journal:  J Exp Med       Date:  2012-08-13       Impact factor: 14.307

10.  SAVI: a statistical algorithm for variant frequency identification.

Authors:  Vladimir Trifonov; Laura Pasqualucci; Enrico Tiacci; Brunangelo Falini; Raul Rabadan
Journal:  BMC Syst Biol       Date:  2013-10-14
View more
  46 in total

Review 1.  Ontogeny, Genetics, Molecular Biology, and Classification of B- and T-Cell Non-Hodgkin Lymphoma.

Authors:  Russell James Hubbard Ryan; Ryan Alan Wilcox
Journal:  Hematol Oncol Clin North Am       Date:  2019-05-18       Impact factor: 3.722

2.  Novel insights into the genetics and epigenetics of MALT lymphoma unveiled by next generation sequencing analyses.

Authors:  Luciano Cascione; Andrea Rinaldi; Alessio Bruscaggin; Chiara Tarantelli; Alberto J Arribas; Ivo Kwee; Lorenza Pecciarini; Afua A Mensah; Valeria Spina; Elaine Y L Chung; Lodovico Terzi di Bergamo; Stephan Dirnhofer; Alexandar Tzankov; Roberto N Miranda; Ken H Young; Alexandra Traverse-Glehen; Gianluca Gaidano; Steven H Swerdlow; Randy Gascoyne; Raul Rabadan; Maurilio Ponzoni; Govind Bhagat; Davide Rossi; Emanuele Zucca; Francesco Bertoni
Journal:  Haematologica       Date:  2019-04-24       Impact factor: 9.941

Review 3.  The role of G protein-coupled receptors in lymphoid malignancies.

Authors:  Adrienne Nugent; Richard L Proia
Journal:  Cell Signal       Date:  2017-08-09       Impact factor: 4.315

Review 4.  Clinical utility of recently identified diagnostic, prognostic, and predictive molecular biomarkers in mature B-cell neoplasms.

Authors:  Arantza Onaindia; L Jeffrey Medeiros; Keyur P Patel
Journal:  Mod Pathol       Date:  2017-06-30       Impact factor: 7.842

5.  G-protein coupled receptor (GPCR) mutations in lymphoid malignancies: linking immune signaling activation and genetic abnormalities.

Authors:  Jose Angel Martinez-Climent
Journal:  Haematologica       Date:  2018-08       Impact factor: 9.941

Review 6.  Advances in targeted therapy for malignant lymphoma.

Authors:  Li Wang; Wei Qin; Yu-Jia Huo; Xiao Li; Qing Shi; John E J Rasko; Anne Janin; Wei-Li Zhao
Journal:  Signal Transduct Target Ther       Date:  2020-03-06

7.  Differences between BCL2-break positive and negative follicular lymphoma unraveled by whole-exome sequencing.

Authors:  A Zamò; J Pischimarov; M Schlesner; P Rosenstiel; R Bomben; H Horn; T Grieb; T Nedeva; C López; A Haake; J Richter; L Trümper; C Lawerenz; W Klapper; P Möller; M Hummel; D Lenze; M Szczepanowski; L Flossbach; M Schreder; V Gattei; G Ott; R Siebert; A Rosenwald; E Leich
Journal:  Leukemia       Date:  2017-08-21       Impact factor: 11.528

8.  Mutations of MAP2K1 are frequent in pediatric-type follicular lymphoma and result in ERK pathway activation.

Authors:  Janine Schmidt; Joan Enric Ramis-Zaldivar; Ferran Nadeu; Blanca Gonzalez-Farre; Alba Navarro; Caoimhe Egan; Ivonne Aidee Montes-Mojarro; Teresa Marafioti; Jose Cabeçadas; Jon van der Walt; Stefan Dojcinov; Andreas Rosenwald; German Ott; Irina Bonzheim; Falko Fend; Elias Campo; Elaine S Jaffe; Itziar Salaverria; Leticia Quintanilla-Martinez
Journal:  Blood       Date:  2017-05-22       Impact factor: 22.113

Review 9.  PTPRD: neurobiology, genetics, and initial pharmacology of a pleiotropic contributor to brain phenotypes.

Authors:  George R Uhl; Maria J Martinez
Journal:  Ann N Y Acad Sci       Date:  2019-01-15       Impact factor: 5.691

10.  Follicular lymphoma t(14;18)-negative is genetically a heterogeneous disease.

Authors:  Dominik Nann; Joan Enric Ramis-Zaldivar; Inga Müller; Blanca Gonzalez-Farre; Janine Schmidt; Caoimhe Egan; Julia Salmeron-Villalobos; Guillem Clot; Sven Mattern; Franziska Otto; Barbara Mankel; Dolors Colomer; Olga Balagué; Vanessa Szablewski; Carmen Lome-Maldonado; Lorenzo Leoncini; Stefan Dojcinov; Andreas Chott; Christiane Copie-Bergman; Irina Bonzheim; Falko Fend; Elaine S Jaffe; Elias Campo; Itziar Salaverria; Leticia Quintanilla-Martinez
Journal:  Blood Adv       Date:  2020-11-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.